ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

– ENB-003 in combination with KEYTRUDA (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC)

– Encouraging results support further development

– Expansion cohort in primary PROC and other refractory advanced cancers (ENB-003 + KEYTRUDA) to commence in 2024

See more here